Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 132

1.

Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.

Chae YK, Davis AA, Raparia K, Agte S, Pan A, Mohindra N, Villaflor V, Giles F.

Clin Lung Cancer. 2018 Sep 25. pii: S1525-7304(18)30253-5. doi: 10.1016/j.cllc.2018.09.008. [Epub ahead of print]

PMID:
30425022
2.

A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors.

Atrafi F, Groen HJM, Byers LA, Garralda E, Lolkema MP, Sangha RS, Viteri S, Chae YK, Camidge DR, Gabrail NY, Hu B, Tian T, Nuthalapati S, Hoening E, He L, Komarnitsky P, Calles A.

Clin Cancer Res. 2018 Oct 16. doi: 10.1158/1078-0432.CCR-18-2014. [Epub ahead of print]

PMID:
30327308
3.

Management of Persistent Pruritus and Lichenoid Reaction Secondary to Nivolumab With Narrowband Ultraviolet B Phototherapy.

Donaldson M, Owen JL, Chae YK, Choi JN.

Front Oncol. 2018 Sep 25;8:405. doi: 10.3389/fonc.2018.00405. eCollection 2018.

4.

Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.

Chae YK, Oh MS.

J Thorac Oncol. 2018 Oct 6. pii: S1556-0864(18)33174-5. doi: 10.1016/j.jtho.2018.09.022. [Epub ahead of print] Review.

PMID:
30296486
5.

Deep and Durable Response With Combination CTLA-4 and PD-1 Blockade in Mismatch Repair (MMR)-proficient Endometrial Cancer.

Oh MS, Chae YK.

J Immunother. 2018 Sep 21. doi: 10.1097/CJI.0000000000000244. [Epub ahead of print]

PMID:
30247204
6.

Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review.

Chae YK, Chiec L, Adney SK, Waitzman J, Costa R, Carneiro B, Matsangou M, Agulnik M, Kopp P, Giles F.

Oncotarget. 2018 Jun 15;9(46):28281-28289. doi: 10.18632/oncotarget.25606. eCollection 2018 Jun 15. Review.

7.

Systematic review and meta-analysis of selected toxicities of approved ALK inhibitors in metastatic non-small cell lung cancer.

Costa RB, Costa RLB, Talamantes SM, Kaplan JB, Bhave MA, Rademaker A, Miller C, Carneiro BA, Mahalingam D, Chae YK.

Oncotarget. 2018 Apr 24;9(31):22137-22146. doi: 10.18632/oncotarget.25154. eCollection 2018 Apr 24.

8.

Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).

Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F.

J Immunother Cancer. 2018 May 16;6(1):39. doi: 10.1186/s40425-018-0349-3. Review.

9.

Immune checkpoint pathways in non-small cell lung cancer.

Chae YK, Arya A, Iams W, Cruz M, Mohindra N, Villaflor V, Giles FJ.

Ann Transl Med. 2018 Mar;6(5):88. doi: 10.21037/atm.2017.09.30. Review.

10.

Anaplastic Lymphoma Kinase Mutation (ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib.

Carneiro BA, Pamarthy S, Shah AN, Sagar V, Unno K, Han H, Yang XJ, Costa RB, Nagy RJ, Lanman RB, Kuzel TM, Ross JS, Gay L, Elvin JA, Ali SM, Cristofanilli M, Chae YK, Giles FJ, Abdulkadir SA.

Clin Cancer Res. 2018 Jun 15;24(12):2732-2739. doi: 10.1158/1078-0432.CCR-18-0332. Epub 2018 Mar 20.

PMID:
29559559
11.

Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma.

Chae YK, Anker JF, Bais P, Namburi S, Giles FJ, Chuang JH.

Oncotarget. 2017 Dec 15;9(8):7949-7960. doi: 10.18632/oncotarget.23742. eCollection 2018 Jan 30.

12.

Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC).

Chae YK, Chang S, Ko T, Anker J, Agte S, Iams W, Choi WM, Lee K, Cruz M.

Sci Rep. 2018 Feb 13;8(1):2918. doi: 10.1038/s41598-018-21061-1.

13.

Overexpression of adhesion molecules and barrier molecules is associated with differential infiltration of immune cells in non-small cell lung cancer.

Chae YK, Choi WM, Bae WH, Anker J, Davis AA, Agte S, Iams WT, Cruz M, Matsangou M, Giles FJ.

Sci Rep. 2018 Jan 18;8(1):1023. doi: 10.1038/s41598-018-19454-3.

14.

Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.

Park W, Kwon D, Saravia D, Desai A, Vargas F, El Dinali M, Warsch J, Elias R, Chae YK, Kim DW, Warsch S, Ishkanian A, Ikpeazu C, Mudad R, Lopes G, Jahanzeb M.

Clin Lung Cancer. 2018 May;19(3):280-288.e4. doi: 10.1016/j.cllc.2017.12.007. Epub 2017 Dec 21.

PMID:
29336998
15.

Cancer immunotherapy in a neglected population: The current use and future of T-cell-mediated checkpoint inhibitors in organ transplant patients.

Chae YK, Galvez C, Anker JF, Iams WT, Bhave M.

Cancer Treat Rev. 2018 Feb;63:116-121. doi: 10.1016/j.ctrv.2017.12.004. Epub 2017 Dec 8. Review.

PMID:
29276997
16.

Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Chae YK, Arya A, Chiec L, Shah H, Rosenberg A, Patel S, Raparia K, Choi J, Wainwright DA, Villaflor V, Cristofanilli M, Giles F.

Oncotarget. 2017 Aug 1;8(59):100863-100898. doi: 10.18632/oncotarget.19809. eCollection 2017 Nov 21. Review.

17.

Molecular Biomarkers of Primary and Acquired Resistance to T-Cell-Mediated Immunotherapy in Cancer: Landscape, Clinical Implications, and Future Directions.

Chae YK, Oh MS, Giles FJ.

Oncologist. 2018 Apr;23(4):410-421. doi: 10.1634/theoncologist.2017-0354. Epub 2017 Dec 14. Review.

PMID:
29242279
18.

Path toward Precision Oncology: Review of Targeted Therapy Studies and Tools to Aid in Defining "Actionability" of a Molecular Lesion and Patient Management Support.

Chae YK, Pan AP, Davis AA, Patel SP, Carneiro BA, Kurzrock R, Giles FJ.

Mol Cancer Ther. 2017 Dec;16(12):2645-2655. doi: 10.1158/1535-7163.MCT-17-0597. Review.

19.

Correlation of tumor mutational burden and treatment outcomes in patients with colorectal cancer.

Pai SG, Carneiro BA, Chae YK, Costa RL, Kalyan A, Shah HA, Helenowski I, Rademaker AW, Mahalingam D, Giles FJ.

J Gastrointest Oncol. 2017 Oct;8(5):858-866. doi: 10.21037/jgo.2017.06.20.

20.

A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.

Mota JM, Collier KA, Barros Costa RL, Taxter T, Kalyan A, Leite CA, Chae YK, Giles FJ, Carneiro BA.

Oncotarget. 2017 Jun 13;8(51):89284-89306. doi: 10.18632/oncotarget.18467. eCollection 2017 Oct 24. Review.

21.

Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.

Costa R, Costa RB, Talamantes SM, Helenoswki I, Carneiro BA, Chae YK, Gradishar WJ, Kurzrock R, Giles FJ.

Oncotarget. 2017 Jun 29;8(40):67782-67789. doi: 10.18632/oncotarget.18847. eCollection 2017 Sep 15.

22.

Pseudoprogression in microsatellite instability-high colorectal cancer during treatment with combination T cell mediated immunotherapy: a case report and literature review.

Chae YK, Wang S, Nimeiri H, Kalyan A, Giles FJ.

Oncotarget. 2017 Jun 3;8(34):57889-57897. doi: 10.18632/oncotarget.18361. eCollection 2017 Aug 22.

23.

Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis.

Chuzi S, Tavora F, Cruz M, Costa R, Chae YK, Carneiro BA, Giles FJ.

Cancer Manag Res. 2017 Jun 14;9:207-213. doi: 10.2147/CMAR.S136818. eCollection 2017. Review.

24.

Relationship between recombinant protein expression and host metabolome as determined by two-dimensional NMR spectroscopy.

Chae YK, Kim SH, Markley JL.

PLoS One. 2017 May 9;12(5):e0177233. doi: 10.1371/journal.pone.0177233. eCollection 2017.

25.

Wnt/beta-catenin pathway: modulating anticancer immune response.

Pai SG, Carneiro BA, Mota JM, Costa R, Leite CA, Barroso-Sousa R, Kaplan JB, Chae YK, Giles FJ.

J Hematol Oncol. 2017 May 5;10(1):101. doi: 10.1186/s13045-017-0471-6. Review.

26.

Nodal Signaling as a Developmental Therapeutics Target in Oncology.

Kalyan A, Carneiro BA, Chandra S, Kaplan J, Chae YK, Matsangou M, Hendrix MJC, Giles F.

Mol Cancer Ther. 2017 May;16(5):787-792. doi: 10.1158/1535-7163.MCT-16-0215. Review.

27.

Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.

Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N, Platanias LC, Gradishar W, Giles FJ, Cristofanilli M.

Mol Cancer Ther. 2017 Jul;16(7):1412-1420. doi: 10.1158/1535-7163.MCT-17-0061. Epub 2017 Apr 26.

28.

Systematic analysis of early phase clinical studies for patients with breast cancer: Inclusion of patients with brain metastasis.

Costa R, Gill N, Rademaker AW, Carneiro BA, Chae YK, Kumthekar P, Gradishar WJ, Kurzrock R, Giles FJ.

Cancer Treat Rev. 2017 Apr;55:10-15. doi: 10.1016/j.ctrv.2017.02.006. Epub 2017 Feb 22. Review.

PMID:
28279895
29.

Developmental Therapeutics Implications of Next-Generation Sequencing in Human Herpesvirus 8-Negative Castleman Disease.

Zhou XA, Chae YK, Giles FJ.

JAMA Dermatol. 2017 May 1;153(5):381-382. doi: 10.1001/jamadermatol.2016.5555. No abstract available.

PMID:
28241212
30.

Developmental therapeutics for patients with breast cancer and central nervous system metastasis: current landscape and future perspectives.

Costa R, Carneiro BA, Wainwright DA, Santa-Maria CA, Kumthekar P, Chae YK, Gradishar WJ, Cristofanilli M, Giles FJ.

Ann Oncol. 2017 Jan 1;28(1):44-56. doi: 10.1093/annonc/mdw532. Review.

PMID:
28177431
31.

Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.

Costa R, Shah AN, Santa-Maria CA, Cruz MR, Mahalingam D, Carneiro BA, Chae YK, Cristofanilli M, Gradishar WJ, Giles FJ.

Cancer Treat Rev. 2017 Feb;53:111-119. doi: 10.1016/j.ctrv.2016.12.010. Epub 2017 Jan 5. Review.

PMID:
28104566
32.

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.

Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M, Giles FJ.

Oncotarget. 2017 Feb 28;8(9):16052-16074. doi: 10.18632/oncotarget.14109. Review.

33.

Developmental therapeutics for inflammatory breast cancer: Biology and translational directions.

Costa R, Santa-Maria CA, Rossi G, Carneiro BA, Chae YK, Gradishar WJ, Giles FJ, Cristofanilli M.

Oncotarget. 2017 Feb 14;8(7):12417-12432. doi: 10.18632/oncotarget.13778. Review.

34.

Repurposing metformin for cancer treatment: current clinical studies.

Chae YK, Arya A, Malecek MK, Shin DS, Carneiro B, Chandra S, Kaplan J, Kalyan A, Altman JK, Platanias L, Giles F.

Oncotarget. 2016 Jun 28;7(26):40767-40780. doi: 10.18632/oncotarget.8194. Review.

35.

A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes.

Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F.

Cancer Immunol Immunother. 2017 Jan;66(1):25-32. doi: 10.1007/s00262-016-1913-7. Epub 2016 Oct 19.

PMID:
27761609
36.

Concordance between genomic alterations assessed by next-generation sequencing in tumor tissue or circulating cell-free DNA.

Chae YK, Davis AA, Carneiro BA, Chandra S, Mohindra N, Kalyan A, Kaplan J, Matsangou M, Pai S, Costa R, Jovanovic B, Cristofanilli M, Platanias LC, Giles FJ.

Oncotarget. 2016 Oct 4;7(40):65364-65373. doi: 10.18632/oncotarget.11692.

37.

Recent Advances and Future Strategies for Immune-Checkpoint Inhibition in Small-Cell Lung Cancer.

Chae YK, Pan A, Davis AA, Mohindra N, Matsangou M, Villaflor V, Giles F.

Clin Lung Cancer. 2017 Mar;18(2):132-140. doi: 10.1016/j.cllc.2016.07.004. Epub 2016 Jul 9. Review.

PMID:
27520630
38.

FGFR3-TACC3 fusion in solid tumors: mini review.

Costa R, Carneiro BA, Taxter T, Tavora FA, Kalyan A, Pai SA, Chae YK, Giles FJ.

Oncotarget. 2016 Aug 23;7(34):55924-55938. doi: 10.18632/oncotarget.10482. Review.

39.

Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Chae YK, Pan A, Davis AA, Raparia K, Mohindra NA, Matsangou M, Giles FJ.

Clin Lung Cancer. 2016 Sep;17(5):350-361. doi: 10.1016/j.cllc.2016.03.011. Epub 2016 Apr 6. Review.

PMID:
27137346
40.

The challenge of developmental therapeutics for adrenocortical carcinoma.

Costa R, Carneiro BA, Tavora F, Pai SG, Kaplan JB, Chae YK, Chandra S, Kopp PA, Giles FJ.

Oncotarget. 2016 Jul 19;7(29):46734-46749. doi: 10.18632/oncotarget.8774. Review.

41.

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Konduri K, Gallant JN, Chae YK, Giles FJ, Gitlitz BJ, Gowen K, Ichihara E, Owonikoko TK, Peddareddigari V, Ramalingam SS, Reddy SK, Eaby-Sandy B, Vavalà T, Whiteley A, Chen H, Yan Y, Sheehan JH, Meiler J, Morosini D, Ross JS, Stephens PJ, Miller VA, Ali SM, Lovly CM.

Cancer Discov. 2016 Jun;6(6):601-11. doi: 10.1158/2159-8290.CD-16-0075. Epub 2016 Apr 21.

42.

Is Personalized Medicine Here?

Carneiro BA, Costa R, Taxter T, Chandra S, Chae YK, Cristofanilli M, Giles FJ.

Oncology (Williston Park). 2016 Apr;30(4):293-303, 307. Review.

43.

The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer.

Chae YK, Gagliato Dde M, Pai SG, Carneiro B, Mohindra N, Giles FJ, Ramakrishnan-Geethakumari P, Sohn J, Liu S, Chen H, Ueno N, Hortobagyi G, Gonzalez-Angulo AM.

PLoS One. 2016 Apr 7;11(4):e0152585. doi: 10.1371/journal.pone.0152585. eCollection 2016.

44.

Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives.

Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, Garrett HB, Agulnik M, Kopp PA, Giles FJ.

Drug Des Devel Ther. 2016 Feb 29;10:873-84. doi: 10.2147/DDDT.S93459. eCollection 2016. Review.

45.

Genomic landscape of DNA repair genes in cancer.

Chae YK, Anker JF, Carneiro BA, Chandra S, Kaplan J, Kalyan A, Santa-Maria CA, Platanias LC, Giles FJ.

Oncotarget. 2016 Apr 26;7(17):23312-21. doi: 10.18632/oncotarget.8196.

46.

Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?

Chae YK, Yousaf M, Malecek MK, Carneiro B, Chandra S, Kaplan J, Kalyan A, Sassano A, Platanias LC, Giles F.

Discov Med. 2015 Dec;20(112):413-27.

47.

Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling.

Chae YK, Chung SY, Davis AA, Carneiro BA, Chandra S, Kaplan J, Kalyan A, Giles FJ.

Oncotarget. 2015 Nov 10;6(35):37117-34. doi: 10.18632/oncotarget.5076. Review.

48.

The correlation between the Trendelenburg position and the stroke volume variation.

Min JH, Lee SE, Lee HS, Chae YK, Lee YK, Kang Y, Je UJ.

Korean J Anesthesiol. 2014 Dec;67(6):378-83. doi: 10.4097/kjae.2014.67.6.378. Epub 2014 Dec 29.

49.

MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis.

Dimou A, Non L, Chae YK, Tester WJ, Syrigos KN.

PLoS One. 2014 Sep 18;9(9):e107677. doi: 10.1371/journal.pone.0107677. eCollection 2014. Review.

50.

Intraarterial mechanical thrombectomy for the treatment of postoperative cerebral infarction: a case report.

Yun JW, Ahn SW, Kim YH, Min J, Choi YS, Chae YK, Lee ES, Kang Y.

Korean J Anesthesiol. 2014 May;66(5):402-6. doi: 10.4097/kjae.2014.66.5.402. Epub 2014 May 26.

Supplemental Content

Support Center